Relationship between the loss of neutralizing antibody binding and fusion activity of the F protein of human respiratory syncytial virus

被引:0
作者
Changbao Liu
Nicole D Day
Patrick J Branigan
Lester L Gutshall
Robert T Sarisky
Alfred M Del Vecchio
机构
[1] Centocor R&D,
[2] Inc,undefined
来源
Virology Journal | / 4卷
关键词
Antigenic Site; Palivizumab; Escape Mutant; Fusion Activity; Human Respiratory Syncytial Virus;
D O I
暂无
中图分类号
学科分类号
摘要
To elucidate the relationship between resistance to HRSV neutralizing antibodies directed against the F protein and the fusion activity of the F protein, a recombinant approach was used to generate a panel of mutations in the major antigenic sites of the F protein. These mutant proteins were assayed for neutralizing mAb binding (ch101F, palivizumab, and MAb19), level of expression, post-translational processing, cell surface expression, and fusion activity. Functional analysis of the fusion activity of the panel of mutations revealed that the fusion activity of the F protein is tolerant to multiple changes in the site II and IV/V/VI region in contrast with the somewhat limited spectrum of changes in the F protein identified from the isolation of HRSV neutralizing antibody virus escape mutants. This finding suggests that aspects other than fusion activity may limit the spectrum of changes tolerated within the F protein that are selected for by neutralizing antibodies.
引用
收藏
相关论文
共 174 条
[1]  
Stensballe LG(2003)Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus Pediatr Infect Dis J 22 S21-32
[2]  
Devasundaram JK(1988)Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies J Virol 62 4232-4238
[3]  
Simoes EA(1989)Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function J Virol 63 2941-2950
[4]  
Anderson LJ(1989)Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins J Virol 63 925-932
[5]  
Bingham P(1987)Respiratory syncytial virus fusion glycoprotein: further characterization of a major epitope involved in virus neutralization Can J Microbiol 33 933-938
[6]  
Hierholzer JC(1997)Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus J Infect Dis 176 1215-1224
[7]  
Beeler JA(2003)Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease J Pediatr 143 532-540
[8]  
van Wyke Coelingh K(2004)Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants J Infect Dis 190 975-978
[9]  
Garcia-Barreno B(2007)Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract J Mol Biol 368 652-665
[10]  
Palomo C(2006)In vitro and in vivo fitness of respiratory syncytial virus monoclonal antibody escape mutants J Virol 80 11651-11657